## BACKGROUND. Percutaneous ethanol injection therapy has been used widely for small hepatocellular carcinoma. This study was undertaken to determine factors predictive of local recurrence or new nodular recurrence in patients with small hepatocellular carcinoma treated with percutaneous ethanol in
Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy
โ Scribed by Maurizio Pompili; Gian Ludovico Rapaccini; Marcello Covino; Giulia Pignataro; Eugenio Caturelli; Domenico Angelo Siena; Maria Rosaria Villani; Augusto Cedrone; Giovanni Gasbarrini
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 130 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
The objective of this study was to identify clinical, biochemical, ultrasound, and/or pathologic parameters capable of predicting survival in a cohort of patients with well compensated cirrhosis and small hepatocellular carcinoma (hcc) who were treated with percutaneous ethanol injection (pei).
Methods:
The study group included 111 patients with child--pugh class a cirrhosis and with one (93 patients) or two (18 patients) hcc nodules measuring < 5 cm in greatest dimension. all patients underwent multisession pei. the prognostic values of pretreatment and post-treatment variables were analyzed using the kaplan-meier method.
Results:
The overall 3-year and 5-year survival rates of 62% and 41%, respectively, were not influenced by age, gender, duration of chronic hepatitis, serum albumin, prothrombin time ratio, total bilirubin, gamma-glutamyl transferase, hepatitis b surface antigen, antihepatitis c virus, hcc size, hcc ultrasound pattern, hcc histologic or cytologic grading, greatest spleen dimension, esophageal varices, or ascites. levels of alpha-fetoprotein (afp) > 14 ng/ml (p < 0.006), alanine aminotransferase > 75 iu/l (p < 0.04), and aspartate aminotransferase > 80 iu/l (p < 0.009) and platelet count < 92 x 10(9)/l (p < 0.02) before treatment were independent predictors of decreased survival. among post-treatment parameters, afp levels 6 months after pei > 13.3 ng/ml (p < 0.003) and hcc recurrence in another segment of the liver (p < 0.04) were linked to decreased survival in univariate analysis.
Conclusions:
Among patients with child--pugh class a cirrhosis with small uninodular or binodular hcc who are treated with multisession pei, those with elevated serum afp and transaminase levels and low platelet count before treatment are characterized by decreased survival. during follow-up, intrahepatic recurrence of the tumor is the main factor affecting survival.
๐ SIMILAR VOLUMES
## BACKGROUND. The authors compared the efficacy of percutaneous microwave coagulation therapy (PMCT) and percutaneous ethanol injection therapy (PEIT) in the treatment of patients with cirrhosis and a solitary nodular hepatocellular carcinoma (HCC) ี 2 cm in greatest dimension. ## METHODS. Of
cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 tolica del Sacro Cuore, Rome, Italy. month after PEI and recurrence of HCC in the same liver segment were also 2 Divisione di Gastroenterologia, IRCCS Casa evaluated. Sollievo della Sofferenza, San Giovanni Rotondo #
## Background: The long term efficacy of combination therapy with transcatheter arterial embolization (tae) followed by percutaneous ethanol injection (pei) was studied in patients with large primary hepatocellular carcinoma (hcc) tumors and cirrhosis. ## Methods: The series included 83 patients